Nanoscope Therapeutics Welcomes Ademola Daramola as New VP of Quality and Compliance

Nanoscope Therapeutics Announces New Leadership in Quality and Compliance

Nanoscope Therapeutics Inc., a leading biotechnology firm focused on developing transformative gene therapies for retinal degenerative diseases, has taken a significant step forward with its latest appointment. Ademola Daramola, D.Sc., has joined the company as the Vice President of Quality and Compliance. This position is crucial as the company moves toward commercializing its groundbreaking optogenetic therapies that aim to restore vision for patients suffering from retinitis pigmentosa (RP) and Stargardt disease.

A Leader in Quality Assurance

Dr. Daramola brings over 20 years of extensive experience that spans a variety of roles within quality assurance, compliance, and operational excellence, particularly in the pharmaceutical and medical device sectors. His impressive background includes pivotal positions at organizations that prioritize customer safety and advocacy, reinforcing the need for adherence to regulatory standards.

Sulagna Bhattacharya, co-founder and CEO of Nanoscope, expressed her enthusiasm about Dr. Daramola’s appointment, noting his rich history of leadership across quality assurance and compliance functions. "His experience, especially with the FDA, will be invaluable as we strive to advance our therapies to market," Bhattacharya stated. This endorsement highlights the strategic importance of Dr. Daramola's role in navigating the complexities of clinical compliance which is paramount in biotech endeavors.

Dr. Daramola’s Previous Experience

Before joining Nanoscope, Dr. Daramola served as the GMP Compliance Leader at the Bill & Melinda Gates Medical Research Institute. In this position, he was vital in ensuring that the institute's biologics, vaccines, and small molecules maintained compliance with essential quality and safety regulations in manufacturing processes.

Additionally, Dr. Daramola spent nearly eight years with the Food and Drug Administration (FDA) as an International Relations Specialist and Consumer Safety Officer, primarily focusing on drug and medical device integrity. His early career at Teva Pharmaceuticals as a chemist has laid the groundwork for a tremendous understanding of industry standards. Academically, Dr. Daramola achieved a doctorate and master's degree in Global Health from Nova Southeastern University, in addition to two bachelor's degrees, one from Barry University and the other from Ondo State University in Nigeria.

The Path Ahead

"Nanoscope is at a pivotal juncture with the upcoming commercialization of our lead candidate, MCO-010," said Dr. Daramola. "Joining this talented team is an exciting opportunity, and I look forward to maintaining the highest standards of quality and compliance to bring life-changing therapies to patients in need.”

Under Dr. Daramola's leadership, Nanoscope aims to ensure that all quality and compliance procedures are meticulously followed as they gear up for the planned Biologics License Application (BLA) submission for MCO-010 in the first half of 2025. This submission is supported by positive results from the RESTORE Phase 2b trial, which have positioned the company for major advancements in the gene therapy landscape.

Nanoscope’s commitment to patient care and adherence to the robust standards of the industry stands as a testament to their goal of restoring vision to countless individuals grappling with retinal degeneration. With Dr. Daramola steering its quality and compliance efforts, the path toward delivering innovative therapies appears brighter than ever.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is at the forefront of developing optogenetic therapies aimed at restoring sight for millions impacted by retinal degenerative conditions. The company has made strides with positive clinical trial results and aims to expand its clinical portfolio, including therapies for conditions like Geographic Atrophy (GA) and Leber Congenital Amaurosis.

As Nanoscope Therapeutics continues on its mission, further announcements regarding clinical trials and product developments are anticipated, drawing significant attention from stakeholders and ensuring readiness in the therapeutic market for retinal diseases.